FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003236239> ?p ?o ?g. }

• W2003236239 endingPage "43" @default.
• W2003236239 startingPage "34" @default.
• W2003236239 abstract "Study Objective. To model the cost-effectiveness of nesiritide compared with dobutamine in patients with decompensated heart failure. Design. Cost-effectiveness analysis. Measurements and Main Results. A decision tree model was derived from randomized clinical trial data and data from a previously published economic study. Four cost-effectiveness analyses were performed: analysis 1—full probabilistic analysis, repeatedly sampled probabilities for 6-month mortality and hospital readmission from distributions based on 95% confidence intervals (CIs); analysis 2—best-case nesiritide analysis, used the limiting values of the 95% CI favorable to nesiritide; analysis 3—best-case dobutamine analysis, used the limiting values of the 95% CI favorable to dobutamine; and analysis 4—replicated the previously published cost-effectiveness study and served as a methodologic control. Fifty-one consecutive Monte Carlo simulations for cohorts of 1000 hypothetical patients were performed for each analysis. Incremental cost, incremental effectiveness, and incremental cost-effectiveness ratios (ICERs) were calculated for nesiritide versus dobutamine. Analysis 1 showed a mean ICER of $767/life-year gained for nesiritide versus dobutamine (incremental cost $251 ± $290, incremental effectiveness 0.33 ± 0.22 yr). The 95% confidence region surrounding this point estimate spanned all four quadrants of the incremental cost-effectiveness scatterplot, suggesting inconclusive results. Nesiritide was the dominant treatment strategy in analysis 2 (incremental cost −$734 ± $106, incremental effectiveness 1.19 ± 0.07 yrs), whereas dobutamine was dominant in analysis 3 (incremental cost $1242 ± $73, incremental effectiveness −0.57 ± 0.05 yr). Analysis 4 was comparable to the previously published cost-effectiveness analysis (incremental cost −$77 ± $87, incremental effectiveness 0.48 ± 0.05 yr). Conclusions. Based on available randomized clinical trial data, nesiritide did not exhibit robust economic superiority over dobutamine. When incorporating the uncertainty (i.e., 95% CIs) in clinical effectiveness as reported in available clinical trial data into the economic analysis, either nesiritide or dobutamine may be the dominant treatment (i.e., more effective at lower cost) for the studied population. Economic analyses of nesiritide and any comparator must account for uncertainty in estimates of cost as well as in clinical effectiveness." @default.
• W2003236239 created "2016-06-24" @default.
• W2003236239 creator A5026681054 @default.
• W2003236239 creator A5043090391 @default.
• W2003236239 creator A5062288568 @default.
• W2003236239 creator A5064006627 @default.
• W2003236239 date "2006-01-01" @default.
• W2003236239 modified "2023-09-27" @default.
• W2003236239 title "Pharmacoeconomic Modeling of Nesiritide versus Dobutamine for Decompensated Heart Failure" @default.
• W2003236239 cites W1975971363 @default.
• W2003236239 cites W1988232724 @default.
• W2003236239 cites W1995573946 @default.
• W2003236239 cites W1995901724 @default.
• W2003236239 cites W2010829142 @default.
• W2003236239 cites W2011613855 @default.
• W2003236239 cites W2013376495 @default.
• W2003236239 cites W2021967123 @default.
• W2003236239 cites W2034619044 @default.
• W2003236239 cites W2038454936 @default.
• W2003236239 cites W2071269728 @default.
• W2003236239 cites W2093781201 @default.
• W2003236239 cites W2103994553 @default.
• W2003236239 cites W2113126233 @default.
• W2003236239 cites W2138854610 @default.
• W2003236239 cites W2142597122 @default.
• W2003236239 cites W2144397934 @default.
• W2003236239 cites W2149507015 @default.
• W2003236239 cites W2162445884 @default.
• W2003236239 cites W2167504169 @default.
• W2003236239 cites W2328167306 @default.
• W2003236239 cites W4361868505 @default.
• W2003236239 cites W2097966545 @default.
• W2003236239 doi "https://doi.org/10.1592/phco.2006.26.1.34" @default.
• W2003236239 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16509026" @default.
• W2003236239 hasPublicationYear "2006" @default.
• W2003236239 type Work @default.
• W2003236239 sameAs 2003236239 @default.
• W2003236239 citedByCount "9" @default.
• W2003236239 countsByYear W20032362392014 @default.
• W2003236239 countsByYear W20032362392015 @default.
• W2003236239 countsByYear W20032362392017 @default.
• W2003236239 countsByYear W20032362392018 @default.
• W2003236239 crossrefType "journal-article" @default.
• W2003236239 hasAuthorship W2003236239A5026681054 @default.
• W2003236239 hasAuthorship W2003236239A5043090391 @default.
• W2003236239 hasAuthorship W2003236239A5062288568 @default.
• W2003236239 hasAuthorship W2003236239A5064006627 @default.
• W2003236239 hasConcept C112930515 @default.
• W2003236239 hasConcept C126322002 @default.
• W2003236239 hasConcept C164705383 @default.
• W2003236239 hasConcept C178853913 @default.
• W2003236239 hasConcept C2775915353 @default.
• W2003236239 hasConcept C2777386981 @default.
• W2003236239 hasConcept C2778198053 @default.
• W2003236239 hasConcept C2781185063 @default.
• W2003236239 hasConcept C3019080777 @default.
• W2003236239 hasConcept C44249647 @default.
• W2003236239 hasConcept C515549039 @default.
• W2003236239 hasConcept C71924100 @default.
• W2003236239 hasConceptScore W2003236239C112930515 @default.
• W2003236239 hasConceptScore W2003236239C126322002 @default.
• W2003236239 hasConceptScore W2003236239C164705383 @default.
• W2003236239 hasConceptScore W2003236239C178853913 @default.
• W2003236239 hasConceptScore W2003236239C2775915353 @default.
• W2003236239 hasConceptScore W2003236239C2777386981 @default.
• W2003236239 hasConceptScore W2003236239C2778198053 @default.
• W2003236239 hasConceptScore W2003236239C2781185063 @default.
• W2003236239 hasConceptScore W2003236239C3019080777 @default.
• W2003236239 hasConceptScore W2003236239C44249647 @default.
• W2003236239 hasConceptScore W2003236239C515549039 @default.
• W2003236239 hasConceptScore W2003236239C71924100 @default.
• W2003236239 hasIssue "1" @default.
• W2003236239 hasLocation W20032362391 @default.
• W2003236239 hasLocation W20032362392 @default.
• W2003236239 hasOpenAccess W2003236239 @default.
• W2003236239 hasPrimaryLocation W20032362391 @default.
• W2003236239 hasRelatedWork W1508665971 @default.
• W2003236239 hasRelatedWork W2000589255 @default.
• W2003236239 hasRelatedWork W2003236239 @default.
• W2003236239 hasRelatedWork W2071269728 @default.
• W2003236239 hasRelatedWork W2110946056 @default.
• W2003236239 hasRelatedWork W2125804349 @default.
• W2003236239 hasRelatedWork W2169806744 @default.
• W2003236239 hasRelatedWork W2318288688 @default.
• W2003236239 hasRelatedWork W2418386531 @default.
• W2003236239 hasRelatedWork W2587215852 @default.
• W2003236239 hasVolume "26" @default.
• W2003236239 isParatext "false" @default.
• W2003236239 isRetracted "false" @default.
• W2003236239 magId "2003236239" @default.
• W2003236239 workType "article" @default.